Botulinumtoxin bei der Behandlung depressiver Störungen

Hawlik, Andreas E.; Freudenmann, Roland W.; Pinkhardt, Elmar H.; Schönfeldt‐Lecuona, Carlos; Gahr, Maximilian

doi:10.1055/s-0033-1356093

Cited by 10 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results confirm that the use of onabotulinumtoxinA in the comorbid patient group is an efficient alternative to treat both diseases as hitherto several times shown for the isolated conditions (i.e. [26,27,28] for depression, [29,30,31,32,33] for migraine) and confirmed through meta-analytic approach studying both conditions separately [6,7,8,9]. Interestingly, onabotulinumtoxinA seems to enfold a slightly different beneficial effect dependent on whether a patient shows just one or both diseases together.…”

Section: Discussionsupporting

confidence: 78%

“…In this case, using a standardized effect size would lead to the comparison of effects that from a rigorous point of view could not be compared. An approach similar to ours has been used in [6,7] and partly in [9,8]. Second, from a clinical perspective, the standardized effect size has a less intuitive interpretation, while score reduction in a scale can easily lead to a clearer evaluation of the effect of the treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Figure4 Figure 4 Comparison of the treatment efficacy with onabotulinumtoxinA in patients monomorbid with migraine or depression and patients co-morbid with both disorders. Data of the patients showing only migraine or depression were extracted from the meta-analyses [6,7,8,9]. Data of comorbid patients were calculated based on the studies [15,16,17,18,19,20,21,22].…”

Section: Figuresmentioning

confidence: 99%

See 2 more Smart Citations

High Efficacy of OnabotulinumtoxinA Treatment in Patients With Comorbid Migraine and Depression: A Meta-analysis

Affatato

Moulin

Pisanu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Migraine and depression are highly prevalent and partly overlapping disorders that cause strong limitations in daily life. Patients tend to respond poorly to the therapies available for these diseases. OnabotulinumtoxinA has been proven to be an effective treatment for both migraine and depression. While many studies have addressed the effect of onabotulinumtoxinA in migraine or depression separately, a growing body of evidences suggest benecial effects also for patients comorbid with migraine and depression. The current meta-analysis systematically investigates to what extent onabotulinumtoxinA is efficient in migraineurs with depression.Methods: A systematic literature search was performed based on PubMed, Scopus and Web of Science from the earliest date till October 30th, 2020. Mean, standard deviation (SD) and sample size have been used to evaluate improvement in depressive symptoms and migraine using random-effects empirical Bayes model. Results: Our search retrieved 259 studies, eight of which met inclusion criteria. OnabotulinumtoxinA injections administered to patients with both chronic migraine and major depressive disorder led to mean reduction of -8.94 points (CI: [-10.04, -7.84], p < 0:01) in the BDI scale, of -5.90 points (CI: [-9.92, -1.88], p < 0:01) in the BDI-II scale and of -6.19 points (CI: [-9.52, -2.86], p < 0:01) in the PHQ-9 scale, when evaluating depressive symptoms. In the case of the migraine-related symptoms, we found mean reductions of -4.10 (CI: [-7.31, -0.89], p = 0.01) points in the HIT6 scale, -32.05 (CI: [-55.96, -8.14], p = 0.01) in the MIDAS scale, -1.7 (CI: [-3.27, -0.13], p = 0.03) points in the VAS scale and of -6.27 (CI: [-8.48, -4.07], p < 0:01) migraine episodes per month. Comorbid patients showed slightly better improvements in BDI, HIT6 scores and migraine frequency compared to monomorbid patients. The latter group manifested better results in MIDAS and VAS scores. Conclusion: Treatment with onabotulinumtoxinA leads to a signicant reduction of disease severity of both chronic migraine and major depressive disorder in patients comorbid with both diseases. Comparative analyses suggest an equivalent strong effect in monomorbid and comorbid patients, with benecial effects specically seen for certain migraine features.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Section: Figuresmentioning

confidence: 99%

See 1 more Smart Citation

High Efficacy of OnabotulinumtoxinA Treatment in Patients With Comorbid Migraine and Depression: A Meta-analysis

Affatato

Moulin

Pisanu

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The parahippocampal gyrus is part of the limbic area, and the limbic lobe and cerebellum are involved in emotion processing [29–31], which plays an important role in depression [34, 35]. Recently, published studies have shown a reduction in depressive symptoms after BoNT-A injection into the glabellar region [20, 21, 36, 37]. In our study, BoNT-A injection induced abnormal spontaneous brain activity in the cerebellum (especially the posterior lobe) and parahippocampal gyrus in patients with botulism, suggesting that BoNT-A could modulate the activity of these brain areas.…”

Section: Discussionmentioning

confidence: 99%

Brain functional changes in patients with botulism after illegal cosmetic injections of botulinum toxin: A resting-state fMRI study

Ban

Wang

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

BackgroundBotulinum toxin type A (BoNT-A) is generally considered safe and is widely used to treat a variety of clinical conditions involving muscle hyperactivity and for cosmetic purposes. However, the effects of BoNT-A poisoning (botulism) on brain function are poorly understood.Methodology/Principal findingsHerein, we investigated brain functions in 9 patients who received illegal cosmetic injections of botulinum and 18 matched controls by combining the analysis methods of regional homogeneity (ReHo) and amplitude of low-frequency fluctuation (ALFF) based on resting-state fMRI. Compared with the controls, the patients with botulism exhibited significantly reduced ReHo values in the left posterior lobe of the cerebellum extending to the right anterior lobe of the cerebellum, as well as in the right anterior lobe of the cerebellum extending to the parahippocampal gyrus and right posterior lobe of the cerebellum. The patients with botulism also showed weakened ALFF values in the right anterior lobe of the cerebellum extending to the left anterior lobe of the cerebellum and right posterior lobe of the cerebellum, as well as in the right anterior lobe of the cerebellum.Conclusions/SignificanceThe results indicate that BoNT-A may modulate cerebral activation in specific areas, which may play roles in both the adverse effects of botulism and the mechanism underlying clinical treatment with BoNT-A.

show abstract

“…According to Hawlik et al (2014), the trial evidence does not confirm unequivocally the reported anti-depressive effect of Botox injections. Blinded, well-designed studies with larger patient cohorts might be necessary.…”

Section: Botox Applications As Anti-depressive Therapy: Psycho-ethicamentioning

confidence: 95%

The Distribution of the ABO and Rhesus Blood Groups among the Albanian Population in the Southwest Part of Kosovo (District of Prizren)

Temaj¹

2020

TANTH

View full text Add to dashboard Cite

Strategies of anti-ageing promise eternal youth and necessitate an ethical foundation of this process. With the help of a hypotheses controlled literature research, this descriptive study considers the poles of happiness and death under psychiatric-ethical aspects. In the Western world the association of age and physical deficits is mostly present. Exemplary, the wrinkle treatment represents the immense actual efforts in reducing the deficits accompanying the process of ageing. Actually, Botox as a well-known anti-ageing nerval toxin is also applied as an antidepressant therapy. The authors call for caution at this, because psychiatry, psychosomatics and psychotherapy dispose well-established alternative antidepressive methods like promoting the factor of resilience at an early stage whereby the self-perceived success in ageing can be enhanced. Besides resilience, humour, self-validation and gratitude should be recognised. Further studies are needed for an evaluation of thanatologic interventions in psychotherapy.

show abstract

Botulinumtoxin bei der Behandlung depressiver Störungen

Cited by 10 publications

References 11 publications

High Efficacy of OnabotulinumtoxinA Treatment in Patients With Comorbid Migraine and Depression: A Meta-analysis

High Efficacy of OnabotulinumtoxinA Treatment in Patients With Comorbid Migraine and Depression: A Meta-analysis

Brain functional changes in patients with botulism after illegal cosmetic injections of botulinum toxin: A resting-state fMRI study

The Distribution of the ABO and Rhesus Blood Groups among the Albanian Population in the Southwest Part of Kosovo (District of Prizren)

Contact Info

Product

Resources

About